In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zeltiq Aesthetics Inc.

Division of Allergan PLC
www.zeltiq.com

Latest From Zeltiq Aesthetics Inc.

Medtech Business Models: All Razor And No Blades – Is “Big Iron” Back In Vogue?

The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.

Market Intelligence Business Strategies

Medical Aesthetics: Key Players In A Largely Untapped Market

Medical aesthetics is a growing, but largely untapped biopharma niche with unique consumer marketing and doctor relationship-building strategies where key players have honed their skills for many years. Allergan's blockbuster Botox dominates, but competitors are gaining ground.

Aesthetics Business Strategies

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics

Appointments: Flex Pharma, Bicycle Therapeutics, Nordic Nanovector, Biogen, CRISPR and NightstaRx

The week's roundup includes the appointment of a new CEO by Flex Pharma and various other high-level appointments by Bicycle Therapeutics, SetPoint Medical, Theravance Biopharma and Nordic Nanovector.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Dermatology
  • Gynecological, Urological
  • Metabolic Disorders
  • Alias(es)
  • Juniper Medical Inc.
  • Zeltiq Aesthetics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Carl J Lamm, VP, Operations
    Brad Hauser, PhD, VP, R&D
    Danika Harrison, VP, Global Mktg.
  • Contact Info
  • Zeltiq Aesthetics Inc.
    Phone: (925) 474-2500
    4410 Rosewood Dr.
    Pleasanton, CA 94588
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register